Insider trading

Period: 120 months Stock: DYN + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

293 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

293 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

293 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

293 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
293 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
293 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

293 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
22 Feb 2024
Rhodes Jason P Director · indirect
Sold on a plan
$2.70M 119,360 at 22.66
1.8%
Planned (10b5-1)
22 Feb 2024
Sold on a plan
$2.70M 119,360 at 22.66
1.8%
Planned (10b5-1)
21 Feb 2024
Rhodes Jason P Director · indirect
Sold on a plan 2×
$4.16M 184,501 at 22.57
2.7%
Planned (10b5-1)
21 Feb 2024
Sold on a plan 2×
$4.16M 184,501 at 22.57
2.7%
Planned (10b5-1)
20 Feb 2024
Rhodes Jason P Director · indirect
Sold on a plan 2×
$3.85M 169,539 at 22.72
2.4%
Planned (10b5-1)
20 Feb 2024
Sold on a plan 2×
$3.85M 169,539 at 22.72
2.4%
Planned (10b5-1)
16 Feb 2024
Rhodes Jason P Director · indirect
Sold on a plan
$3.77M 162,707 at 23.14
2.3%
Planned (10b5-1)
16 Feb 2024
Sold on a plan
$3.77M 162,707 at 23.14
2.3%
Planned (10b5-1)
15 Feb 2024
Rhodes Jason P Director · indirect
Sold on a plan 2×
$4.25M 177,906 at 23.89
2.4%
Planned (10b5-1)
15 Feb 2024
Sold on a plan 2×
$4.25M 177,906 at 23.89
2.4%
Planned (10b5-1)
12 Feb 2024
Farwell Wildon Chief Medical Officer
Sold on a plan
$137.71K 5,493 at 25.07
3.3%
Planned (10b5-1)
26 Jan 2024
McNeill Jonathan Chief Business Officer
Sold on a plan 2×
$490.51K 20,000 at 24.53
12.2%
Planned (10b5-1)
26 Jan 2024
Scalzo Richard William SVP, Head of Finance & Admin.
Sold on a plan
$316.42K 13,000 at 24.34
9.5%
Planned (10b5-1)
26 Jan 2024
Farwell Wildon Chief Medical Officer
Sold on a plan
$2.50K 100 at 25.00
0.1%
Planned (10b5-1)
9 Jan 2024
Kersten Dirk Director · indirect
Bought 2×
$30.00M 1,714,285 at 17.50
36.5%
First buy on file
4 Jan 2024
Brumm Joshua T CEO & President
Sold on a plan 2×
$4.05M 218,536 at 18.51
27.2%
Planned (10b5-1)
4 Jan 2024
Beskrovnaya Oxana Chief Scientific Officer
Sold on a plan
$769.67K 42,453 at 18.13
21.3%
Planned (10b5-1)
4 Jan 2024
McNeill Jonathan Chief Business Officer
Sold on a plan
$36.24K 2,009 at 18.04
1.4%
Planned (10b5-1)
3 Jan 2024
Brumm Joshua T CEO & President
Sold on a plan 3×
$986.96K 51,183 at 19.28
8.0%
Planned (10b5-1)
3 Jan 2024
Beskrovnaya Oxana Chief Scientific Officer
Sold on a plan 3×
$860.31K 45,326 at 18.98
20.4%
Planned (10b5-1)
3 Jan 2024
McNeill Jonathan Chief Business Officer
Sold on a plan 2×
$337.06K 17,991 at 18.74
11.1%
Planned (10b5-1)
3 Jan 2024
Scalzo Richard William SVP, Head of Finance & Admin.
Sold on a plan
$244.53K 13,000 at 18.81
9.5%
Planned (10b5-1)
2 Jan 2024
McNeill Jonathan Chief Business Officer
Sold on a plan
$155.89K 11,900 at 13.10
7.7%
Planned (10b5-1)
14 Dec 2023
Sold on a plan
$28.56K 2,376 at 12.02
1.9%
Planned (10b5-1)
12 Dec 2023
Farwell Wildon Chief Medical Officer
Sold on a plan
$10.32K 978 at 10.55
0.6%
Planned (10b5-1)
11 Dec 2023
Brumm Joshua T See Remarks
Sold at will
$81.31K 7,585 at 10.72
1.3%
Not planned
11 Dec 2023
Farwell Wildon Chief Medical Officer
Sold on a plan
$18.10K 1,688 at 10.72
1.0%
Planned (10b5-1)
11 Dec 2023
HIGH SUSANNA GATTI Chief Operating Officer
Sold at will
$17.32K 1,616 at 10.72
0.9%
Not planned
11 Dec 2023
Beskrovnaya Oxana Chief Scientific Officer
Sold at will
$15.73K 1,467 at 10.72
0.8%
Not planned
11 Dec 2023
Sold at will
$14.79K 1,380 at 10.72
1.1%
Not planned
11 Dec 2023
McNeill Jonathan Chief Business Officer
Sold at will
$13.35K 1,245 at 10.72
0.8%
Not planned
6 Dec 2023
Sold on a plan
$22.48K 1,872 at 12.01
1.4%
Planned (10b5-1)
4 Dec 2023
Sold on a plan
$8.18K 681 at 12.01
0.5%
Planned (10b5-1)
2 Nov 2023
HIGH SUSANNA GATTI Chief Operating Officer
Sold at will
$73.55K 9,939 at 7.40
9.5%
Not planned
18 Sep 2023
Brumm Joshua T See Remarks
Sold at will
$113.22K 12,032 at 9.41
4.9%
Not planned
18 Sep 2023
HIGH SUSANNA GATTI Chief Operating Officer
Sold at will
$25.14K 2,672 at 9.41
2.5%
Not planned
18 Sep 2023
Beskrovnaya Oxana Chief Scientific Officer
Sold at will
$13.51K 1,436 at 9.41
1.7%
Not planned
18 Sep 2023
Sold at will
$12.14K 1,290 at 9.41
3.1%
Not planned
18 Sep 2023
McNeill Jonathan Chief Business Officer
Sold at will
$11.87K 1,261 at 9.41
2.0%
Not planned
12 Sep 2023
Brumm Joshua T See Remarks
Sold at will
$79.87K 7,672 at 10.41
3.0%
Not planned
12 Sep 2023
Farwell Wildon Chief Medical Officer
Sold at will
$17.77K 1,707 at 10.41
1.9%
Not planned
12 Sep 2023
HIGH SUSANNA GATTI Chief Operating Officer
Sold at will
$17.02K 1,635 at 10.41
1.5%
Not planned
12 Sep 2023
Beskrovnaya Oxana Chief Scientific Officer
Sold at will
$15.45K 1,484 at 10.41
1.7%
Not planned
12 Sep 2023
Sold at will
$14.54K 1,397 at 10.41
3.2%
Not planned
12 Sep 2023
McNeill Jonathan Chief Business Officer
Sold on a plan
$13.18K 1,266 at 10.41
2.0%
Planned (10b5-1)
15 Jun 2023
Sold at will
$120.30K 10,000 at 12.03
18.7%
Not planned
13 Jun 2023
Sold at will 2×
$532.88K 41,390 at 12.87
43.6%
Not planned
13 Jun 2023
Farwell Wildon Chief Medical Officer
Sold at will
$21.11K 1,698 at 12.43
1.8%
Not planned
13 Jun 2023
HIGH SUSANNA GATTI Chief Operating Officer
Sold at will
$20.20K 1,625 at 12.43
1.5%
Not planned
13 Jun 2023
Beskrovnaya Oxana Chief Scientific Officer
Sold at will
$18.33K 1,475 at 12.43
1.7%
Not planned
Showing 201–250 of 293. ← Newer Page 5 of 6 Older →